The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer

BACKGROUND: Larotrectinib and entrectinib are FDA-approved therapies for patients with non-small cell lung cancer (NSCLC) with neurotrophic receptor tyrosine kinase gene fusion (TRK fusion-positive) whose cancer has metastasized and progressed. Early evidence indicates that these targeted therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Roth, Joshua A., Carlson, Josh J., Xia, Fang, Williamson, Todd, Sullivan, Sean D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2020
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391271/
https://www.ncbi.nlm.nih.gov/pubmed/32329651
http://dx.doi.org/10.18553/jmcp.2020.20045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391271/
https://www.ncbi.nlm.nih.gov/pubmed/32329651
http://dx.doi.org/10.18553/jmcp.2020.20045

Ejemplares similares